Abstract
The prevalence of chronic pain increases with age, exceeding 50% in individuals aged ≥65 years. Nonsteroidal anti-inflammatory drugs (NSAIDs) are a mainstay of chronic pain management but carry significant dose-related risks of cardiovascular, renal, haematological and other systemic adverse events (AEs). Older patients have an increased risk of these AEs and are more likely to take multiple medications that can potentially interact with NSAIDs. In particular, older patients are more likely to have cardiovascular disease and a natural age-related decline in renal function, increasing the risks of cardiovascular, haematological and renal AEs. Given these risks, recent guidelines for the management of chronic pain in the elderly recommend using NSAIDs rarely and only in carefully selected patients. NSAIDs currently available in the US fall into three categories: nonselective NSAIDs that act via inhibition of cyclo-oxygenase (COX)-1 and COX-2; celecoxib, a selective inhibitor of COX-2; and topical NSAIDs that inhibit both COX-1 and COX-2 but result in much less systemic NSAID exposure than oral formulations. Topical NSAIDs have demonstrated efficacy similar to oral NSAIDs, with an incidence of AEs similar to placebo; however, these agents are an option only in patients with localized pain in superficial joints. Safe pain management in older patients therefore requires cautious choice of selective and nonselective oral NSAIDs, topical NSAIDs or non-NSAID analgesics. This article discusses the risks and benefits of NSAID therapy, reviews its mechanism of action as the source of adverse effects and provides recommendations for maximizing NSAID safety, particularly in older patients. Articles cited in this review were identified via a search of PubMed (January 2005 to November 2009) and a manual search of reference lists from the articles identified in that search. Priority was given to articles discussing NSAID use in older populations, clinical trials of high quality, reports on NSAID safety and AEs, and treatment guidelines.
Similar content being viewed by others
References
Parsons S, Breen A, Foster NE, et al. Prevalence and comparative troublesomeness by age of musculoskeletal pain in different body locations. Fam Pract 2007 Sep; 24(4): 308–16
Tsang A, Von Korff M, Lee S, et al. Common chronic pain conditions in developed and developing countries: gender and age differences and comorbidity with depression-anxiety disorders. J Pain 2008 Oct; 9(10): 883–91
Cosby AG, Hitt HC, Thornton-Neaves T, et al. Profiles of pain in Mississippi: results from the Southern Pain Prevalence Study. J Miss State Med Assoc 2005 Oct; 46(10): 301–9
Watkins EA, Wollan PC, Melton 3rd LJ, et al. A population in pain: report from the Olmsted County health study. Pain Med 2008 Mar; 9(2): 166–74
Breivik H, Collett B, Ventafridda V, et al. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain 2006 May; 10(4): 287–333
Barkin RL, Barkin SJ, Barkin DS. Perception, assessment, treatment, and management of pain in the elderly. Clin Geriatr Med 2005 Aug; 21(3): 465–90, v
Cavazos JM, Naik AD, Woofter A, et al. Barriers to physician adherence to nonsteroidal anti-inflammatory drug guidelines: a qualitative study. Aliment Pharmacol Ther 2008 Sep 15; 28(6): 789–98
Dewar AL, Gregg K, White MI, et al. Navigating the health care system: perceptions of patients with chronic pain. Chronic Dis Can 2009; 29(4): 162–8
Appelboom T. Arthropathy in art and the history of pain management through the centuries to cyclooxygenase-2 inhibitors. Rheumatology 2002 Apr; 41Suppl. 1: 28–34
Scanzello CR, Moskowitz NK, Gibofsky A. The post-NSAID era: what to use now for the pharmacologic treatment of pain and inflammation in osteoarthritis. Curr Rheumatol Rep 2008 Jan; 10(1): 49–56
Hippisley-Cox J, Coupland C, Logan R. Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005 Dec 3; 331(7528): 1310–6
Kearney PM, Baigent C, Godwin J, et al. Do selective cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006 Jun 3; 332(7553): 1302–8
Barkin RL, Buvanendran A. Focus on the COX-1 and COX-2 agents: renal events of nonsteroidal and anti-inflammatory drugs-NSAIDs. Am J Ther 2004 Mar–Apr; 11(2): 124–9
Antman EM, Bennett JS, Daugherty A, et al. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 2007 Mar 27; 115(12): 1634–42
Rostom A, Goldkind L, Laine L. Nonsteroidal antiinflammatory drugs and hepatic toxicity: a systematic review of randomized controlled trials in arthritis patients. Clin Gastroenterol Hepatol 2005 May; 3(5): 489–98
Franceschi M, Di Mario F, Leandro G, et al. Acid-related disorders in the elderly. Best Pract Res Clin Gastroenterol 2009; 23(6): 839–48
Zhang W, Doherty M, Leeb BF, et al. EULAR evidence based recommendations for the management of hand osteoarthritis: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007; 66(3): 377–88
Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008; 16(2): 137–62
Voltaren® Gel 1% (diclofenac sodium topical gel): US prescribing information. Parsippany (NJ): Novartis Consumer Health, Inc., 2007
Towheed TE. Pennsaid therapy for osteoarthritis of the knee: a systematic review and metaanalysis of randomized controlled trials [see comment]. J Rheumatol 2006 Mar; 33(3): 567–73
Kienzler J, Gold M, Nollevaux F. Systemic bioavailability of topical diclofenac sodium gel 1% versus oral diclofenac sodium in healthy volunteers. J Clin Pharmacol New Drugs 2010; 50: 50–61
Arora S, Wagner JG, Herbert M. Myth: parenteral ketorolac provides more effective analgesia than oral ibuprofen. CJEM 2007 Jan; 9(1): 30–2
Shatsky M. Evidence for the use of intramuscular injections in outpatient practice. Am Fam Physician 2009 Feb 15; 79(4): 297–300
Bhamb B, Brown D, Hariharan J, et al. Survey of select practice behaviors by primary care physicians on the use of opioids for chronic pain. Curr Med Res Opin 2006 Sep; 22(9): 1859–65
Upshur CC, Luckmann RS, Savageau JA. Primary care provider concerns about management of chronic pain in community clinic populations. J Gen Intern Med 2006 Jun; 21(6): 652–5
Dalinka MK, Stewart V, Bomalaski JS, et al. Periarticular calcifications in association with intra-articular corticosteroid injections. Radiology 1984 Dec; 153(3): 615–8
Haraldsson BT, Langberg H, Aagaard P, et al. Corticosteroids reduce the tensile strength of isolated collagen fascicles. Am J Sports Med 2006 Dec; 34(12): 1992–7
Karalezli N, Ogun TC, Kartal S, et al. The pain associated with intraarticular hyaluronic acid injections for trapeziometacarpal osteoarthritis. Clin Rheumatol 2007 Apr; 26(4): 569–71
Lemont H, Hetman J. Cutaneous foot depigmentation following an intra-articular steroid injection. J Am Podiatr Med Assoc 1991 Nov; 81(11): 606–7
Orapred ODT™ (prednisolone sodium phosphate orally disintegrating tablets): US prescribing information. Eden Prairie (MN): Cima Labs Inc., 2006
American Geriatrics Society Panel on Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc 2009 Aug; 57(8): 1331–46
Boers M, Tangelder MJ, van Ingen H, et al. The rate of NSAID-induced endoscopic ulcers increases linearly but not exponentially with age: a pooled analysis of 12 randomised trials. Ann Rheum Dis 2007 Mar; 66(3): 417–8
Bardhan KD, Royston C. Time, change and peptic ulcer disease in Rotherham, UK. Dig Liver Dis 2008 Jul; 40(7): 540–6
Higham J, Kang JY, Majeed A. Recent trends in admissions and mortality due to peptic ulcer in England: increasing frequency of haemorrhage among older subjects. Gut 2002 Apr; 50(4): 460–4
Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002 Jan 5; 359(9300): 14–22
Singh G, Fort JG, Goldstein JL, et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. Am J Med 2006 Mar; 119(3): 255–66
Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000 Nov 23; 343(21): 1520–8
Schnitzer TJ, Burmester GR, Mysler E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004 Aug 21–27; 364(9435): 665–74
Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal antiinflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study. A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000 Sep 13; 284(10): 1247–55
Caldwell B, Aldington S, Weatherall M, et al. Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med 2006 Mar; 99(3): 132–40
Juni P, Nartey L, Reichenbach S, et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004 Dec 4–10; 364(9450): 2021–9
Motsko SP, Rascati KL, Busti AJ, et al. Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk. Drug Saf 2006; 29(7): 621–32
Forman JP, Stampfer MJ, Curhan GC. Non-narcotic analgesic dose and risk of incident hypertension in US women. Hypertension 2005 Sep; 46(3): 500–7
Johnson AG, Nguyen TV, Day RO. Do nonsteroidal antiinflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994 Aug 15; 121(4): 289–300
Pavlicevic I, Kuzmanic M, Rumboldt M, et al. Interaction between antihypertensives and NSAIDs in primary care: a controlled trial. Can J Clin Pharmacol 2008 Fall; 15(3): e372–82
Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005 Jun 11; 330(7504): 1366
Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics — 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007 Feb 6; 115(5): e69–171
Solomon DH, Glynn RJ, Rothman KJ, et al. Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups. Arthritis Rheum 2008 Aug 15; 59(8): 1097–104
Cheetham TC, Levy G, Niu F, et al. Gastrointestinal safety of nonsteroidal antiinflammatory drugs and selective cyclooxygenase-2 inhibitors in patients on warfarin. Ann Pharmacother 2009 Nov; 43(11): 1765–73
Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol 2008 Nov; 103(11): 2890–907
Kearney D, Byrne A, Crean P, et al. Optimal suppression of thromboxane A(2) formation by aspirin during percutaneous transluminal coronary angioplasty: no additional effect of a selective cyclooxygenase-2 inhibitor. J Am Coll Cardiol 2004 Feb 18; 43(4): 526–31
Cheng Y, Wang M, Yu Y, et al. Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J Clin Invest 2006 May; 116(5): 1391–9
Gooch K, Culleton BF, Manns BJ, et al. NSAID use and progression of chronic kidney disease. Am J Med 2007 Mar; 120(3): 280 e1-7
Huerta C, Castellsague J, Varas-Lorenzo C, et al. Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population. Am J Kidney Dis 2005 Mar; 45(3): 531–9
Rubenstein JH, Laine L. Systematic review: the hepatotoxicity of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2004 Aug 15; 20(4): 373–80
Malhotra S, Karan RS, Pandhi P, et al. Drug related medical emergencies in the elderly: role of adverse drug reactions and non-compliance. Postgrad Med J 2001 Nov; 77(913): 703–7
Tulner LR, Frankfort SV, Gijsen GJ, et al. Drug-drug interactions in a geriatric outpatient cohort: prevalence and relevance. Drugs Aging 2008; 25(4): 343–55
Hajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in elderly patients. Am J Geriatr Pharmacother 2007 Dec; 5(4): 345–51
Preskorn SH, Silkey B, Shah R, et al. Complexity of medication use in the Veterans Affairs healthcare system: part I. Outpatient use in relation to age and number of prescribers. J Psychiatr Pract 2005 Jan; 11(1): 5–15
Capone ML, Sciulli MG, Tacconelli S, et al. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol 2005 Apr 19; 45(8): 1295–301
Farkouh ME, Greenberg JD, Jeger RV, et al. Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib. Ann Rheum Dis 2007 Jun; 66(6): 764–70
Gengo FM, Rubin L, Robson M, et al. Effects of ibuprofen on the magnitude and duration of aspirin’s inhibition of platelet aggregation: clinical consequences in stroke prophylaxis. J Clin Pharmacol 2008 Jan; 48(1): 117–22
MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003 Feb 15; 361(9357): 573–4
Renda G, Tacconelli S, Capone ML, et al. Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease. Clin Pharmacol Ther 2006 Sep; 80(3): 264–74
Pavlicevic I, Kuzmanic M, Rumboldt M, et al. Interaction between antihypertensives and NSAIDs in primary care: a controlled trial. Can J Clin Pharmacol 2008 Fall; 15(3): e372–82
Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009 Mar 4; 301(9): 937–44
Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009 Mar 31; 180(7): 713–8
Barkin RL, Schwer WA, Barkin SJ. Pharmacotherapeutic management of acute and chronic pain. In: Rakel RE, editor. Textbook of family medicine. 7th ed. Philadelphia (PA): Saunders Elsevier, 2007: 305–16
Seibert K, Zhang Y, Leahy K, et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci U S A 1994 Dec 6; 91(25): 12013–7
Kargman S, Charleson S, Cartwright M, et al. Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts. Gastroenterology 1996 Aug; 111(2): 445–54
Zimmermann KC, Sarbia M, Schror K, et al. Constitutive cyclooxygenase-2 expression in healthy human and rabbit gastric mucosa. Mol Pharmacol 1998 Sep; 54(3): 536–40
Takeeda M, Hayashi Y, Yamato M, et al. Roles of endogenous prostaglandins and cyclooxygenase izoenzymes in mucosal defense of inflamed rat stomach. J Physiol Pharmacol 2004 Mar; 55 (1 Pt 2): 193–205
Brzozowski T, Konturek PC, Konturek SJ, et al. Classic NSAID and selective cyclooxygenase (COX)-1 and COX-2 inhibitors in healing of chronic gastric ulcers. Microsc Res Tech 2001 Jun 1; 53(5): 343–53
Massó González EL, Patrignani P, Tacconelli S, et al. Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding. Arthritis Rheum 2010 Jun; 62(6): 1592–601
Ye W, Zhang H, Hillas E, et al. Expression and function of COX isoforms in renal medulla: evidence for regulation of salt sensitivity and blood pressure. Am J Physiol Renal Physiol 2006 Feb; 290(2): F542–9
Cybulsky AV. Cyclooxygenases, prostanoids, and glomerular injury: complex relationships. J Am Soc Nephrol 2007 Feb; 18(2): 367–8
Barkin RL. The pharmacist’s role in the nonsteroidal antiinflammatory drug selection process. Am J Ther 2008 Nov–Dec; 15Suppl. 10: S17–9
Abuelo JG. Normotensive ischemic acute renal failure. N Engl J Med 2007 Aug 23; 357(8): 797–805
Catella-Lawson F, McAdam B, Morrison BW, et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 1999 May; 289(2): 735–41
Morham SG, Langenbach R, Loftin CD, et al. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 1995 Nov 3; 83(3): 473–82
Nantel F, Meadows E, Denis D, et al. Immunolocalization of cyclooxygenase-2 in the macula densa of human elderly. FEBS Lett 1999 Sep 3; 457(3): 475–7
Khan KN, Stanfield KM, Harris RK, et al. Expression of cyclooxygenase-2 in the macula densa of human kidney in hypertension, congestive heart failure, and diabetic nephropathy. Ren Fail 2001 May–Jul; 23(3–4): 321–30
Evans JM, McGregor E, McMahon AD, et al. Non-steroidal anti-inflammatory drugs and hospitalization for acute renal failure. QJM 1995 Aug; 88(8): 551–7
Zhang J, Ding EL, Song Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. JAMA 2006 Oct 4; 296(13): 1619–32
Swan SK, Rudy DW, Lasseter KC, et al. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet: a randomized, controlled trial. Ann Intern Med 2000 Jul 4; 133(1): 1–9
Radi ZA, Ostroski R. Pulmonary and cardiorenal cyclooxygenase-1 (COX-1), -2 (COX-2), and microsomal prostaglandin E synthase-1 (mPGES-1) and -2 (mPGES-2) expression in a hypertension model. Mediators Inflamm 2007; Vol. 2007: article ID 85091, doi: 10.1155/2007/85091
Rossat J, Maillard M, Nussberger J, et al. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther 1999 Jul; 66(1): 76–84
Garcia Rodriguez LA, Tacconelli S, Patrignani P. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 2008 Nov 11; 52(20): 1628–36
Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005 Mar 17; 352(11): 1081–91
Pathak A, Boveda S, Defaye P, et al. Celecoxib-associated torsade de pointes. Ann Pharmacother 2002 Jul–Aug; 36(7–8): 1290–1
Likar R, Wittels M, Molnar M, et al. Pharmacokinetic and pharmacodynamic properties of tramadol IR and SR in elderly patients: a prospective, age-group-controlled study. Clin Ther 2006 Dec; 28(12): 2022–39
European Medicines Agency. European Medicines Agency recommends withdrawal of the marketing authorisations for lumiracoxib-containing medicines [press release]. 2007 Dec 14
Facts & Comparisons online [online]. Available from URL: http://www.factsandcomparisons.com/ [Accessed 2010 Mar 1]
National Collaborating Centre for Chronic Conditions. Osteoarthritis: the care and management of osteoarthritis in adults. London: Royal College of Physicians, 2008
Zhang W, Nuki G, Moskowitz RW, et al. OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage 2010 Apr; 18(4): 476–99
Sciulli MG, Seta F, Tacconelli S, et al. Effects of acetaminophen on constitutive and inducible prostanoid biosynthesis in human blood cells. Br J Pharmacol 2003 Feb; 138(4): 634–41
Altman R, Barkin RL. Topical therapy for osteoarthritis: clinical and pharmacologic perspectives. Postgrad Med 2009 Mar; 121(2): 139–47
Barkin RL. Reducing cardiovascular risks of nonsteroidal anti-inflammatory drugs by using topical formulations [letter]. Am J Cardiol 2009 Nov 1; 104(9): 1315
Richy F, Bruyere O, Ethgen O, et al. Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach. Ann Rheum Dis 2004 Jul; 63(7): 759–66
Chan AT, Manson JE, Albert CM, et al. Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation 2006 Mar 28; 113(12): 1578–87
Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med 1999 May 31; 106(5B): 13S–24S
Riess W, Schmid K, Botta L, et al. The percutaneous absorption of diclofenac. Arzneimittelforschung 1986 Jul; 36(7): 1092–6
Barthel HR, Haselwood D, Longley S, et al. Diclofenac sodium topical gel 1% in patients with primary knee osteoarthritis: a randomized, double-blind, placebo-controlled trial. Semin Arthritis Rheum 2009 Dec; 39(3): 203–12
Tugwell PS, Wells GA, Shainhouse JZ. Equivalence study of a topical diclofenac solution (Pennsaid) compared with oral diclofenac in symptomatic treatment of osteoarthritis of the knee: a randomized controlled trial. J Rheumatol 2004 Oct; 31(10): 2002–12
Altman RD, Dreiser RL, Fisher CL, et al. Diclofenac sodium gel in patients with primary hand osteoarthritis: a randomized, double-blind, placebo-controlled trial. J Rheumatol 2009 Sep; 36(9): 1991–9
Simon LS, Grierson LM, Naseer Z, et al. Efficacy and safety of topical diclofenac containing dimethyl sulfoxide (DMSO) compared with those of topical placebo, DMSO vehicle and oral diclofenac for knee osteoarthritis. Pain 2009 Apr 18; 143(3): 238–45
Bennell KL, Hinman RS, Metcalf BR, et al. Efficacy of physiotherapy management of knee joint osteoarthritis: a randomised, double blind, placebo controlled trial. Ann Rheum Dis 2005 Jun; 64(6): 906–12
Galer BS, Rowbotham M, Perander J, et al. Topical diclofenac patch relieves minor sports injury pain: results of a multicenter controlled clinical trial. J Pain Symptom Manage 2000 Apr; 19(4): 287–94
Zacher J, Burger K, Farber L, et al. Topical diclofenac Emulgel versus oral ibuprofen in the treatment of active osteoarthritis of the finger joints (Heberden’s and/or Bouchard’s nodes): double-blind, controlled, randomized study. Aktuel Rheumatology 2001; 26: 7–14
Altman RD, Gold M, Wieman MS. Safety and efficacy of topical diclofenac sodium 1% gel in seniors and younger patients with hand osteoarthritis. American Academy of Pain Medicine 26th Annual Meeting; 2010 Feb 3–6; San Antonio (TX)
Baraf HS, Gloth FM, Clark MB, et al. Diclofenac sodium topical gel 1% in knee osteoarthritis: comparison of safety and efficacy in patients aged <65 and ≥65 years. American Geriatrics Society Annual Scientific Meeting; 2009 Apr 29–May 2; Chicago (IL)
Barkin RL, Barkin D. Pharmacologic management of acute and chronic pain: focus on drug interactions and patient-specific pharmacotherapeutic selection. South Med J 2001 Aug; 94(8): 756–70
Rosenthal NR, Silverfield JC, Wu SC, et al. Tramadol/acetaminophen combination tablets for the treatment of pain associated with osteoarthritis flare in an elderly patient population. J Am Geriatr Soc 2004 Mar; 52(3): 374–80
Vorsanger G, Xiang J, Jordan D, et al. Post hoc analysis of a randomized, double-blind, placebo-controlled efficacy and tolerability study of tramadol extended release for the treatment of osteoarthritis pain in geriatric patients. Clin Ther 2007; 29 Suppl.: 2520–35
Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 1985 Apr; 33(4): 278–85
Rowe JW, Andres R, Tobin JD, et al. The effect of age on creatinine clearance in men: a cross-sectional and longitudinal study. J Gerontol 1976 Mar; 31(2): 155–63
Lewis SC, Langman MJ, Laporte JR, et al. Dose-response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis based on individual patient data. Br J Clin Pharmacol 2002 Sep; 54(3): 320–6
Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993 Feb 22; 153(4): 477–84
Karlsson J, Pivodic A, Aguirre D, et al. Efficacy, safety, and tolerability of the cyclooxygenase-inhibiting nitric oxide donator naproxcinod in treating osteoarthritis of the hip or knee. J Rheumatol 2009 Jun; 36(6): 1290–7
White WB, Schnitzer TJ, Fleming R, et al. Effects of the cyclooxygenase inhibiting nitric oxide donator naproxcinod versus naproxen on systemic blood pressure in patients with osteoarthritis. Am J Cardiol 2009 Sep 15; 104(6): 840–5
de Abajo FJ, Garcia Rodriguez LA. Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. BMC Clin Pharmacol 2001; 1: 1
Loke YK, Trivedi AN, Singh S. Meta-analysis: gastrointestinal bleeding due to interaction between selective serotonin uptake inhibitors and non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2008 Jan 1; 27(1): 31–40
Abebe W. Herbal medication: potential for adverse interactions with analgesic drugs. J Clin Pharm Ther 2002 Dec; 27(6): 391–401
Yoon SL, Schaffer SD. Herbal, prescribed, and over-the-counter drug use in older women: prevalence of drug interactions. Geriatr Nurs 2006 Mar–Apr; 27(2): 118–29
Acknowledgements
Jeffrey Coleman, MA, and Robert Gatley, MD, of Complete Healthcare Communications, Inc. (Chadds Ford, PA, USA) provided editorial support for this article (literature search, document retrieval, medical writing and copy editing), with funding from Endo Pharmaceuticals Inc., Chadds Ford, PA, USA. Endo Pharmaceuticals made no contribution to the content of this article. None of the authors had any direct or indirect commercial financial incentive associated with publishing the article. The authors have no conflicts of interest that are directly relevant to the content of this review.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Barkin, R.L., Beckerman, M., Blum, S.L. et al. Should Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) be Prescribed to the Older Adult?. Drugs Aging 27, 775–789 (2010). https://doi.org/10.2165/11539430-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11539430-000000000-00000